Supplementary Marterial 2. Summary of gastrointestinal disorders, nausea, and vomiting in Clinical Trial ONO-2745-06. (at least 10% of patients; SAF) Values are number (proportion).

	Remimazolam 6 mg/kg/h (n = 31)		Remimazolam 12 mg/kg/h (n = 31)	
Event*	**AE**	**ADR**	**AE**	**ADR**
Gastrointestinal disorders	10 (32.3%)	8 (25.8%)	8 (25.8%)	5 (16.1%)
Nausea	10 (32.3%)	8 (25.8%)	5 (16.1%)	4 (12.9%)
Vomiting	7 (12.7%)	7 (12.7%)	5 (16.1%)	4 (12.9%)

*Coded using Preferred Term and System Organ Class according to the Medical Dictionary for Regulatory Activities (MedDRA)
ADR, adverse drug reaction; AE, adverse event; SAF, safety population

The authors translated the table from Japanese to English with the approval of the rights holders.

Pharmaceuticals and Medical Devices Agency. Remimazolam besilate, Summary of Application Materials. Tokyo: Government [Internet] c2004 [2021 Oct 19], p160-259, Japanese. Available from https://www.pmda.go.jp/drugs/2020/P20200120002/index.html.